

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization  
International Bureau



(43) International Publication Date  
27 February 2003 (27.02.2003)

PCT

(10) International Publication Number  
**WO 03/015787 A1**

(51) International Patent Classification<sup>7</sup>: **A61K 31/517**,  
31/422, 31/4045, 31/48, A61P 29/00, 25/06 // (A61K  
31/517, 31:422) (A61K 31/517, 31:4045) (A61K 31/517,  
31:48)

(74) Common Representative: **BOEHRINGER INGEL-  
HEIM PHARMA KG**; Binger Strasse 173, 55216  
Ingelheim am Rhein (DE).

(21) International Application Number: PCT/EP02/08993

(22) International Filing Date: 10 August 2002 (10.08.2002)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:  
101 39 410.1 17 August 2001 (17.08.2001) DE

(81) Designated States (*national*): AE, AG, AL, AM, AT, AU,  
AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU,  
CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH,  
GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC,  
LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW,  
MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG,  
SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ,  
VN, YU, ZA, ZM, ZW.

(84) Designated States (*regional*): ARIPO patent (GH, GM,  
KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW),  
Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM),  
European patent (AT, BE, BG, CH, CY, CZ, DE, DK, EE,  
ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK,  
TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GQ,  
GW, ML, MR, NE, SN, TD, TG).

(71) Applicant (*for all designated States except US*):  
**BOEHRINGER INGELHEIM PHARMA KG**  
[DE/DE]; Binger Strasse 173, 55216 Ingelheim am  
Rhein (DE).

(72) Inventors; and

(75) Inventors/Applicants (*for US only*): **DOODS,**  
**Henri** [NL/DE]; Freiherr-von-König-Strasse 6, 88447  
Warthausen (DE). **RUDOLF, Klaus** [DE/DE]; Öschweg  
11, 88447 Warthausen (DE). **EBERLEIN, Wolfgang**  
[DE/DE]; Obere Au 6, 88400 Biberach (DE).

Published:

— with international search report

For two-letter codes and other abbreviations, refer to the "Guid-  
ance Notes on Codes and Abbreviations" appearing at the begin-  
ning of each regular issue of the PCT Gazette.

(54) Title: USE OF BIBN4096 IN COMBINATION WITH OTHER ANTIMIGRAINE DRUGS FOR THE TREATMENT OF MI-  
GRAINE

(57) Abstract: The present invention relates to a method of treatment or prevention of headache, migraine or cluster headaches, which method comprises co-administration of a therapeutically effective amount of the compound A = 1-[N<sup>2</sup>-[3,5-Di-bromo-N-[[4-(3,4-dihydro-2(1 H)-oxochinazolin-3-yl)-1-piperidiny]-carbonyl]-D-tyrosyl]-L-lysyl]-4-(4-pyridinyl)-piperazine [BIBN4096BS] or a physiologically acceptable salt thereof and a therapeutically effective amount of a second active antimigraine drug, particularly sumatriptan, zolmitriptan or dihydroergotamin or a physiologically acceptable salt thereof, as well as to the corresponding pharmaceutical compositions and the preparation thereof.

WO 03/015787 A1

## Use of BIBN4096 in combination with other antimigraine drugs for the treatment of migraine

---

### Field of the invention

Migraine is one of the most common neurological disorders, involving periodical attacks of headache and nausea as well as a plethora of other symptoms. Although considerable progress has been made, the pathophysiology of migraine is still not understood. However, several observations point to an involvement of Calcitonin Gene-Related Peptide (CGRP). Migraine headache involves the activation of the trigeminal system and dilatation of cranial vessels. CGRP is localized to neurons in the trigeminal ganglia and CGRP levels are increased during a migraine attack, presumably causing the vasodilation observed. Accordingly, it is conceivable that inhibition of CGRP-evoked dilatation of the cranial vessels may provide a novel treatment for migraine headache.

Widely used antimigraine drugs are the so-called „triptans“, e.g. sumatriptan and zolmitriptan. These compounds elicit their antimigraine effects due to their vasoconstrictive properties and presumably their inhibition of the release of the neuropeptide calcitonin gene related peptide (CGRP) (Ferrari, M. D., Saxena, P. R. (1995), 5-HT<sub>1</sub> receptors in migraine pathophysiology and treatment, *Eur. J. Neurology*, 2, 5-21; Johnson, K. W., Phebus, L. A., Cohen, M. L. (1998), Serotonin in migraine: Theiroes, animal models and emerging therapies, *Progress in Drug Research*, Vol. 51, 220-244), the levels of which are assumed to be increased during a migraine attack (Edvinsson, L., Goadsby, P. J. (1994), Neuropeptides in migraine and cluster headache, *Cephalgia*, 14(5), 320-327). A completely novel approach to treat migraine is the use of CGRP antagonists (Doods, H., Hallermayer, G., Wu, D., Entzeroth, M., Rudolf, K., Engel, W., Eberlein, W. (2000), Pharmacological profile of BIBN4096BS, the first selective small molecule CGRP antagonist, *Br. J. Pharmacol.*, 129, 420-423).

- 2 -


### Background of the Invention

WO 98/11128 discloses modified amino acids having CGRP-antagonistic properties, their use and methods for their preparation as well as their use for the production and purification of antibodies and as labelled compounds in RIA and ELISA assays and as diagnostic or analytic auxiliary agents in neurotransmitter research. In view of their pharmacological properties the modified amino acids are thus suitable for acute and prophylactic treatment of headache, particularly migraine and cluster headaches.

### Summary of the Invention

Unexpectedly, it was found that in a model which is considered to predict the antimigraine effects of drugs the combination of two drugs with a completely different mode of action, namely a 5-HT<sub>1B/1D</sub> agonist or an ergot alkaloid and the CGRP antagonist disclosed in the WO 98/11128 A1, namely

A = 1-[N<sup>2</sup>-[3,5-Dibromo-N-[[4-(3,4-dihydro-2(1H)-oxochinazolin-3-yl)-1-piperidiny]-carbonyl]-D-tyrosyl]-L-lysyl]-4-(4-pyridinyl)-piperazine [BIBN4096BS],



results in a highly significant better effect compared to the effect of one drug alone.

- 3 -

**Detailed Description of the Invention**

As a first aspect the present invention provides a method of treatment or prevention of indications selected from the group consisting of headache, migraine and cluster headaches, which method comprises co-administration of a therapeutically effective amount of BIBN4096BS or a physiologically acceptable salt thereof and a  
5 therapeutically effective amount of another active antimigraine drug (A) to a person in need of such treatment.

For this purpose, drug (A) can be selected from the group consisting of antiemetics,  
10 prokinetics, neuroleptics, antidepressants, neurokinin-antagonists, anti-convulsants, histamine-H<sub>1</sub>-receptor antagonists, antimuscarinics,  $\beta$ -blockers,  $\alpha$ -agonists and  $\alpha$ -antagonists, ergot alkaloids, mild analgesics, non-steroidal antiphlogistics, corticosteroids, calcium-antagonists and 5-HT<sub>1B/1D</sub>-agonists.

15 A non-steroidal antiphlogistic may be selected from the group consisting of acclofenac, acemetacin, acetylsalicylic acid, azathioprin, celecoxib, diclofenac, diflunisal, fenbufen, fenoprofen, flurbiprofen, ibuprofen, indometacin, ketoprofen, leflunomid, lornoxicam, mefenamic acid, meloxicam, naproxen, phenylbutazon, piroxicam, sulfasalazin, zomepirac or the pharmaceutically acceptable salts thereof,

20 as 5-HT<sub>1B/1D</sub>-agonists may be used, for example, almotriptan, avitriptan, eletriptan, frovatriptan, naratriptan, rizatriptan, sumatriptan or zolmitriptan or the pharmaceutically acceptable salts thereof and

25 suitable ergot alkaloids are, for example, ergotamine and dihydroergotamine.

Additional active substances which may be considered for the above-mentioned combinations as drug (A) component include, for example, metoclopramide, domperidon, diphenhydramine, cyclizine, promethazine, chlorpromazine,  
30 dexamethasone, flunarizine, dextropropoxyphene, meperidine, propranolol, nadolol, atenolol, clonidine, indoramine, carbamazepine, phenytoin, valproate, amitriptylin, lidocaine or diltiazem.

- 4 -

As a preferred embodiment in the method according to the invention drug (A) is selected from the group consisting of ergot alkaloids and 5-HT<sub>1B/1D</sub>-agonists, especially preferred are dihydroergotamine, sumatriptan and zolmitriptan, most preferred is sumatriptan or the physiologically acceptable salts thereof.

5

As a further preferred embodiment in the method according to the invention drug (A) is selected from the group consisting of non-steroidal antiphlogistics, especially preferred is meloxicam or the physiologically acceptable salts thereof.

- 10 The dosage for the combined migraine drug (A) is appropriately 1/50 of the lowest dose normally recommended up to 1/1 of the normally recommended dosage, preferably 1/50 to 1/6 and more preferably 1/20 to 1/10, by orally, nasally, subcutaneous or intravenous route. The normally recommended dose for the combined migraine drug (A) should be understood to be the dose disclosed in Rote
- 15 Liste Win® 2001/I, Editio Cantor Verlag Aulendorf.

- According to the invention BIBN4096BS or a physiologically acceptable salt thereof may be administered by intravenous or subcutaneous route in a dosage of 0.0001 to 3 mg/kg of body weight or by oral, nasal or inhalative route in a dosage of 0.1 to 10
- 20 mg/kg of body weight once, twice or trice a day, in combination with

sumatriptan or a physiologically acceptable salt thereof which may be administered by oral route in a dosage of 0.03 to 1.43 mg/kg of body weight once, twice or trice a day or

25

by intravenous or subcutaneous route in a dosage of 0.002 to 0.09 mg/kg of body weight once or twice a day or

- by rectal route in a dosage of 0.007 to 0.36 mg/kg of body weight once or twice a
- 30 day or

- 5 -

by nasal route in a dosage of 0.006 to 0.29 mg/kg of body weight once or twice a day or in combination with

5 Zolmitriptan or a physiologically acceptable salt thereof which may be administered by oral route in a dosage of 0.0007 to 0.036 mg/kg of body weight once or twice a day or

10 in combination with dihydroergotamine or a physiologically acceptable salt thereof which may be administered by oral route in a dosage of 0.001 to 0.07 mg/kg of body weight once or twice a day or

15 in combination with meloxicam or a physiologically acceptable salt thereof which may be administered by oral route in a dosage of 0.004 to 0.21 mg/kg of body weight once a day.

20 In a preferred embodiment of the invention BIBN4096BS or a physiologically acceptable salt thereof may be administered by intravenous or subcutaneous route in a dosage of 0.0001 to 3 mg/kg of body weight or by oral, nasal or inhalative route in a dosage of 0.1 to 10 mg/kg of body weight once, twice or trice a day, in combination with

25 sumatriptan or a physiologically acceptable salt thereof which may be administered by oral route in a dosage of 0.03 to 0.24 mg/kg of body weight once, twice or trice a day or

by intravenous or subcutaneous route in a dosage of 0.002 to 0.015 mg/kg of body weight once or twice a day or

30 by rectal route in a dosage of 0.007 to 0.06 mg/kg of body weight once or twice a day or

- 6 -

by nasal route in a dosage of 0.006 to 0.048 mg/kg of body weight once or twice a day or

in combination with Zolmitriptan or a physiologically acceptable salt thereof which  
5 may be administered by oral route in a dosage of 0.0007 to 0.006 mg/kg of body weight once or twice a day or

in combination with dihydroergotamine or a physiologically acceptable salt thereof which may be administered by oral route in a dosage of 0.001 to 0.01 mg/kg of body  
10 weight once or twice a day or

in combination with meloxicam or a physiologically acceptable salt thereof which may be administered by oral route in a dosage of 0.004 to 0.036 mg/kg of body weight once a day.

15

In a more preferred embodiment of the invention BIBN4096BS or a physiologically acceptable salt thereof may be administered by intravenous or subcutaneous route in a dosage of 0.0001 to 3 mg/kg of body weight or by oral, nasal or inhalative route in a dosage of 0.1 to 10 mg/kg of body weight once, twice or trice a day, in  
20 combination with

sumatriptan or a physiologically acceptable salt thereof which may be administered by oral route in a dosage of 0.075 to 0.143 mg/kg of body weight once, twice or trice a day or

25

by intravenous or subcutaneous route in a dosage of 0.005 to 0.009 mg/kg of body weight once or twice a day or

by rectal route in a dosage of 0.0175 to 0.036 mg/kg of body weight once or twice a  
30 day or

- 7 -

by nasal route in a dosage of 0.015 to 0.029 mg/kg of body weight once or twice a day or

in combination with Zolmitriptan or a physiologically acceptable salt thereof which  
5 may be administered by oral route in a dosage of 0.00175 to 0.0036 mg/kg of body weight once or twice a day or

in combination with dihydroergotamine or a physiologically acceptable salt thereof which may be administered by oral route in a dosage of 0.0025 to 0.007 mg/kg of  
10 body weight once or twice a day or

in combination with meloxicam or a physiologically acceptable salt thereof which may be administered by oral route in a dosage of 0.01 to 0.02 mg/kg of body weight once a day.

15

The present invention provides as a second aspect a pharmaceutical composition for treating or preventing headache, migraine or cluster headaches comprising a therapeutically effective amount of BIBN4096BS or a physiologically acceptable salt thereof and an antimigraine drug (A) selected from the group consisting of  
20 sumatriptan, zolmitriptan and dihydroergotamin or a physiologically acceptable salt thereof as a combined preparation for simultaneous or sequential administration.

A pharmaceutical composition according to the invention may comprise a single dosage unit of 0.1 to 10 mg of BIBN4096BS and

25

a single dosage unit of 1 to 100 mg of sumatriptan or

a single dosage unit of 0.1 to 2.5 mg of zolmitriptan or

30 a single dosage unit of 0.1 to 5 mg of dihydroergotamin or

a single dosage unit of 7.5 to 15 mg of meloxicam.

- 8 -

All doses or dosage units of a physiologically acceptable salt of an active compound mentioned hereinbefore should be understood as the dose or dosage of the active compound itself.

5

Furthermore, a pharmaceutical composition according to the invention may be a kit of parts for treating or preventing headache, migraine or cluster headaches, which kit comprises

- 10 (a) a first containment containing a pharmaceutical composition comprising a therapeutically effective amount of BIBN4096BS or a physiologically acceptable salt thereof and one or more pharmaceutically acceptable diluents and/or carriers; and
- (b) a second containment containing a pharmaceutical composition comprising sumatriptan, zolmitriptan or dihydroergotamin or a  
15 physiologically acceptable salt thereof and one or more pharmaceutically acceptable diluents and/or carriers.

A preferred kit of parts comprises sumatriptan in the second containment.

- 20 A third aspect of the present invention is the use of BIBN4096BS or a physiologically acceptable salt thereof in combination with another active antimigraine drug (A) for the manufacture of a pharmaceutical composition for treating or preventing headache, migraine or cluster headaches. Drug (A) and preferred embodiments thereof as well as pharmaceutical compositions are  
25 mentioned hereinbefore under the first and second aspect of the invention. Most preferred with respect to all aspects of the invention is the combination of BIBN4096BS with sumatriptan or of physiologically acceptable salts thereof.

Several of the drug (A) components mentioned hereinbefore are already on the  
30 market, e.g. sumatriptan is sold under the trade name imigran<sup>®</sup>, zolmitriptan is sold under the trade name ascotop<sup>®</sup> and dihydroergotamin and the pharmaceutically acceptable salts thereof under the trade name agit<sup>®</sup>.

- 9 -

BIBN4096BS can be administered using for instance pharmaceutical formulations disclosed in WO 98/11128 or using one of the following pharmaceutical formulations:

- 5 capsules for powder inhalation containing 1 mg of active substance,
- inhalable solution for nebulisers containing 1 mg of active substance,
- propellant gas-operated metering aerosol containing 1 mg of active substance,
- 10 nasal spray containing 1 mg of active substance,
- tablets containing 20 mg of active substance,
- 15 capsules containing 20 mg of active substance,
- aqueous solution for nasal application containing 10 mg of active substance,
- aqueous solution for nasal application containing 5 mg of active substance, or
- 20 suspension for nasal application containing 20 mg of active substance.

#### Example 1

- 25 In order to examine the pharmacological activity of combinations according to the invention the following experiments have been carried out:

#### Measurement of facial skin blood flow

- 30 Facial skin blood flow was measured by a modified method described by Escott et al. (Escott, K. J., Beattie, D. T., Connor, H. E., Brain, S. D. (1995), Trigeminal ganglion stimulation increases facial skin blood flow in the rat: a major role for calcitonin gene-related peptide, *Brain Research*, 669(1), 93-99). Fasted male wistar

- 10 -

rats (strain CHbb:THOM, 280-320g) were anaesthetized with sodium pentobarbitone (initially with 60 mg/kg i.p. and maintained throughout the experiment with an intraperitoneal infusion of 30 mg/kg/h through a 23 G needle using a solution of 10 mg/ml). Both sides of the buccal area of the facial skin were  
5 shaved and depilated with a commercial depilatory cream (Pilca, Schwarzkopf & Henkel, 40551 Düsseldorf, Germany). The trachea was cannulated and the animals were artificially respired (80 strokes/min) with room air supplemented with oxygen. The body temperature was maintained at 37°C by an automated heating pad. The left femoral artery and the left femoral vein were cannulated for the continuous  
10 measurement of arterial blood pressure and intravenous administration of test compounds, respectively. Neuromuscular blockade was achieved by intravenous administration of pancuronium bromide (1mg/kg/0.5ml, 5 min prior to each electrical stimulation). Heart rate was derived from the blood pressure signal. Blood pressure and heart rate were continuously monitored throughout the course of the experiment  
15 to assess the level of anaesthesia and to monitor the cardiovascular effects of the drugs used in this study.

The animals were placed in a stereotaxic frame and a longitudinal incision was made in the scalp. A small hole was drilled in the skull (left or right) and a bipolar  
20 electrode (Rhodes SNEX-100 supplied by David Kopf Instruments, Tujunga, 91042 California, U.S.A.) was lowered using a micromanipulator, into the trigeminal ganglion (0.32 cm dorsal to bregma,  $\pm$  0.30 cm lateral from the midline and 0.95 cm below the dural surface). The position of the electrodes in the trigeminal ganglia were checked visually at the end of each experiment following removal of the brain.  
25 The trigeminal ganglion was stimulated at 10 Hz, 1 mA, 1 msec for 30 seconds using a stimulator supplied by Hugo Sachs Elektronik (79232 March-Hugstetten, Germany). Microvascular blood flow changes in the facial skin were measured by Laser Doppler flowmetry with a Periflux laser doppler system (PeriFLUX 4001, wave length 780 nm; time constant 3 s, Perimed AB, Järfälla, S-17526, Sweden).  
30 Standard laser doppler probes (PROBE 408) were positioned on either side of the face approximately 0.5 cm below the centre of the eye, an area innervated by the maxillary branch (V2) of the trigeminal nerve. Blood flow changes were measured

- 11 -

as flux in arbitrary units and expressed as area under the flux curve (mm<sup>2</sup>) according to Escott et al. (1995).

#### Experimental protocol

- 5 After 30 min of equilibration, the animals were subjected to three periods of electrical stimulation, separated by a 30 min interval. The first stimulation was used as a control for the subsequent stimulations. Saline, single compound or the combination were administered intravenously 5 min prior to the second stimulation.
- 10 The results are given in the following table 1. They show that the improved potency of the combination of 5-HT<sub>1B/1D</sub> agonists or other antimigraine drugs in general with a CGRP antagonist would allow higher efficacy, would allow lower doses of each compound resulting in similar efficacy with less side effects and the addition of the two mechanisms might result in less headache recurrence.

15

- 12 -

**Table 1:** Effect of BIBN 4096 BS in combination with other antimigraine drugs on facial skin vasodilation induced by electrical trigeminal ganglion stimulation in the rat.

treatment	% of trigeminus stimulation	n	% inhibition compared to control value
saline (control)	82.7 $\pm$ 4.4	11	-
BIBN 4096 BS (0.03 mg/kg)	60.3 $\pm$ 5.1	8	27.1
Sumatriptan (1.0 mg/kg)	68.8 $\pm$ 6.8	7	16.8
BIBN 4096 BS + Sumatriptan (0.03 mg + 1.0 mg)/kg	26.6 $\pm$ 5.4 <sup>a</sup>	6	67.8
Zolmitriptan (0.1 mg/kg)	55.6 $\pm$ 4.8	6	32.8
BIBN 4096 BS + Zolmitriptan (0.03 mg + 0.1 mg)/kg	27.3 $\pm$ 6.0 <sup>b</sup>	6	67.0
DHE (0.1 mg/kg)	60.4 $\pm$ 4.1	6	27.0
BIBN 4096 BS + DHE (0.03 mg + 0.1 mg)/kg	20.9 $\pm$ 3.1 <sup>c</sup>	6	74.7

DHE = Dihydroergotamin

<sup>a</sup> significant,  $p < 0.001$ , compared to Sumatriptan

<sup>b</sup> significant,  $p < 0.01$ , compared to Zolmitriptan

<sup>c</sup> significant,  $p < 0.001$ , compared to DHE

- 13 -

The Examples which follow describe pharmaceutical preparations which contain as active substance BIBN4096BS or a pharmaceutically acceptable salt thereof:

5    Example 2

Capsules for powder inhalation with 1 mg of active substance

Composition:

10    1 capsule for powder inhalation contains:

active substance	1.0 mg
lactose	20.0 mg
hard gelatine capsules	<u>50.0 mg</u>
	71.0 mg

15

Method of preparation:

The active substance is ground to the particle size needed for inhalation. The ground active substance is homogeneously mixed with the lactose. The mixture is packed into hard gelatine capsules.

20

Example 3

Inhalable solution for Respimat® with 1 mg of active substance

25    Composition:

1 spray contains:

active substance	1.0 mg
benzalkonium chloride	0.002 mg
disodium edetate	0.0075 mg
30    purified water ad	15.0 µl

- 14 -

Method of preparation:

The active substance and benzalkonium chloride are dissolved in water and packed in Respimat<sup>®</sup> cartridges.

5 Example 4Inhalable solution for nebulisers with 1 mg of active substance

## Composition:

## 10 1 vial contains:

active substance	0.1 g
sodium chloride	0.18 g
benzalkonium chloride	0.002 g
purified water ad	20.0 ml

15

Method of preparation:

Active substance, sodium chloride and benzalkonium chloride are dissolved in water.

20 Example 5Propellant gas-operated metering aerosol with 1 mg of active substance

## Composition:

## 25 1 spray contains:

active substance	1.0 mg
lecithin	0.1 %
propellant gas ad	50.0 µl

- 15 -

Method of preparation:

The micronised active substance is homogeneously suspended in the mixture of lecithin and propellant gas. The suspension is transferred into a pressurised container with a metering valve.

5

Example 6Nasal spray with 1 mg of active substance

## 10 Composition:

1 spray jet contains

active substance	1.0 mg
mannitol	5.0 mg
disodium edetate	0.05 mg
15 ascorbic acid	1.0 mg
purified water ad	0.1 ml

Method of preparation:

20 The active substance and the excipients are dissolved in water and transferred into a suitable container.

Example 7Injectable solution with 5 mg of active substance per 5 ml

25

## Composition:

active substance in basic form	5 mg
acid/salt-forming agent in the amount needed to form a neutral salt	q.s.
30 glucose	250 mg
human serum albumin	10 mg
glycofurol	250 mg

- 16 -

water for injections ad

5 ml

Preparation:

5 Dissolve the glycofurool and glucose in water for injections (Wfi); add human serum albumin; add salt-forming agent; dissolve active substance with heating; make up to specified volume with Wfi; transfer into ampoules under nitrogen gas.

Example 8

10 Injectable solution for subcutaneous administration containing 5 mg of active substance per 1 ml

Composition:

active substance	5 mg
15 glucose	50 mg
polysorbate 80 = Tween 80	2 mg
water for injections ad	1 ml

Preparation:

20 Dissolve glucose and polysorbate in water for injections; dissolve active substance with heating or using ultrasound; make up to specified volume with Wfi; transfer into ampoules under inert gas.

Example 9

25

Injectable solution containing 100 mg of active substance per 10 ml

Composition:

active substance	100 mg
30 monopotassium dihydrogen phosphate = KH <sub>2</sub> PO <sub>4</sub>	12 mg
disodium hydrogen phosphate	

- 17 -

	= Na <sub>2</sub> HPO <sub>4</sub> ·2H <sub>2</sub> O	2 mg
	sodium chloride	180 mg
	human serum albumin	50 mg
	polysorbate 80	20 mg
5	water for injections ad	10 ml

Preparation:

Dissolve polysorbate 80, sodium chloride, monopotassium dihydrogen phosphate and disodium hydrogen phosphate in water for injections (Wfi); add human serum  
10 albumin; dissolve active substance with heating; make up to specified volume with Wfi; transfer into ampoules.

Example 1015 Lyophilisate containing 10 mg of active substanceComposition:

	active substance in basic form	10 mg
	acid/salt-forming agent in the amount needed	
20	to form a neutral salt	q.s.
	mannitol	300 mg
	water for injections ad	2 ml

Preparation:

25 Dissolve mannitol in water for injections (Wfi); add salt-forming agent; dissolve active substance with heating; make up to specified volume with Wfi; transfer into vials; freeze-dry.

Solvent for lyophilisate:

30	polysorbate 80 = Tween 80	20 mg
	mannitol	200 mg
	water for injections ad	10 ml

- 18 -

Preparation:

Dissolve polysorbate 80 and mannitol in water for injections (Wfi); transfer into ampoules.

5

Example 11Lyophilisate containing 5 mg of active substance10 Composition:

active substance in basic form 5 mg

polar or nonpolar solvent

(which can be removed

by freeze-drying) ad

1 ml

15

Preparation:

Dissolve active substance in suitable solvent; transfer into vials; freeze-dry.

Solvent for lyophilisate:

20 polysorbate 80 = Tween 80

5 mg

mannitol

100 mg

water for injections ad

2 ml

Preparation:

25 Dissolve polysorbate 80 and mannitol in water for injections (Wfi); transfer into ampoules.

- 19 -

Example 12Tablets containing 20 mg of active substance

## 5 Composition:

active substance	20 mg
lactose	120 mg
maize starch	40 mg
magnesium stearate	2 mg
10 Povidone K 25	18 mg

Preparation:

Homogeneously mix the active substance, lactose and maize starch; granulate with  
an aqueous solution of Povidone; mix with magnesium stearate; press in a tablet  
15 press; weight of tablet 200 mg.

Example 13Capsules containing 20 mg of active substance

20

## Composition:

active substance	20 mg
maize starch	80 mg
highly dispersed silica	5 mg
25 magnesium stearate	2.5 mg

Preparation:

Homogeneously mix the active substance, maize starch and silica; mix with magne-  
sium stearate; transfer mixture into size 3 hard gelatine capsules in a capsule filling  
30 machine.

- 20 -

Example 14Suppositories containing 50 mg of active substance

## 5 Composition:

active substance	50 mg
hard fat (Adeps solidus) q.s. ad	1700 mg

Preparation:

- 10 Melt the hard fat at about 38°C; homogeneously disperse the ground active substance in the molten hard fat; after cooling to about 35°C, pour into chilled moulds.

Example 1515 Aqueous solution for nasal administration containing 10 mg of active substance

## Composition:

active substance	10.0 mg
hydrochloric acid in the amount needed to form a neutral salt	
20 methyl parahydroxybenzoate (PHB)	0.01 mg
propyl parahydroxybenzoate (PHB)	0.005 mg
purified water ad	1.0 ml

Preparation:

- 25 The active substance is dissolved in purified water; hydrochloric acid is added until the solution is clear; methyl and propyl PHB are added; the solution is made up to the specified volume with purified water; the solution is filtered sterile and transferred into a suitable container.

30

- 21 -

Example 16Aqueous solution for nasal administration containing 5 mg of active substance

5	Composition:	
	active substance	5 mg
	1,2-propanediol	300 mg
	hydroxyethylcellulose	5 mg
	sorbic acid	1 mg
10	purified water ad	1 ml

Preparation:

The active substance is dissolved in 1,2-propanediol; a hydroxyethyl-cellulose solution in purified water containing sorbic acid is prepared and added to the solution of active substance; the solution is filtered sterile and transferred into a suitable container.

Example 17Aqueous solution for intravenous administration containing 5 mg of active substance

	Composition:	
	active substance	5 mg
	1,2-propanediol	300 mg
25	mannitol	50 mg
	water for injections (Wfi) ad	1 ml

Preparation:

The active substance is dissolved in 1,2-propanediol; the solution is made up to approximately the specified volume with Wfi; the mannitol is added and made up to approximately the specified volume with Wfi; the solution is filtered sterile, transferred into individual containers and autoclaved.

- 22 -

Example 18Liposomal formulation for intravenous injection containing 7.5 mg of active substance

5

## Composition:

	active substance	7.5 mg
	egg lecithin, e.g. Lipoid E 80	100.0 mg
	cholesterol	50.0 mg
10	glycerol	50.0 mg
	water for injections ad	1.0 ml

Preparation:

The active substance is dissolved in a mixture of lecithin and cholesterol; the solution is added to a mixture of glycerol and Wfl and homogenised by high pressure homogenisation or by the Microfluidizer technique; the liposomal formulation obtained is transferred into a suitable container under aseptic conditions.

20 Example 19Suspension for nasal administration containing 20 mg of active substance

## Composition:

25	active substance	20.0 mg
	carboxymethylcellulose (CMC)	20.0 mg
	sodium monohydrogen phosphate/sodium dihydrogen phosphate buffer pH 6.8	q.s.
	sodium chloride	8.0 mg
30	methyl parahydroxybenzoate	0.01 mg
	propyl parahydroxybenzoate	0.003 mg
	purified water ad	1.0 ml

- 23 -

Preparation:

The active substance is suspended in an aqueous CMC solution; the other ingredients are added successively to the suspension and the suspension is topped up to the specified volume with purified water.

Example 20Aqueous solution for subcutaneous administration with 10 mg of active substance

10

Composition:

active substance	10.0 mg
sodium monohydrogen phosphate/sodium dihydrogen phosphate buffer q.s. ad pH	7.0
15 sodium chloride	4.0 mg
water for injections ad	0.5 ml

Preparation:

The active substance is dissolved in the phosphate buffer solution, after the addition of the common salt the solution is made up to the specified volume with water. The solution is filtered sterile, transferred into a suitable container and autoclaved.

Example 21

25 Aqueous suspension for subcutaneous administration containing 5 mg of active substance

Composition:

active substance	5.0 mg
30 polysorbate 80	0.5 mg
water for injections	0.5 ml

- 24 -

Preparation:

The active substance is suspended in the polysorbate 80 solution and comminuted to a particle size of about 1  $\mu\text{m}$  using a suitable dispersing technique (e.g. wet grinding, high pressure homogenisation, microfluidisation, etc.). The suspension is  
5 transferred into a corresponding container under aseptic conditions.

### Patent Claims

1. A method of treatment or prevention of indications selected from the group  
5 consisting of headache, migraine and cluster headaches, which method comprises  
co-administration of a therapeutically effective amount of BIBN4096BS or a  
physiologically acceptable salt thereof and a therapeutically effective amount of  
another active antimigraine drug (A) to a person in need of such treatment.
- 10 2. The method according to claim 1, characterized in that drug (A) is selected from  
the group consisting of antiemetics, prokinetics, neuroleptics, antidepressants,  
neurokinin-antagonists, anti-convulsants, histamine-H1-receptor antagonists,  
antimuscarinics,  $\beta$ -blockers,  $\alpha$ -agonists and  $\alpha$ -antagonists, ergot alkaloids, mild  
analgesics, non-steroidal antiphlogistics, corticosteroids, calcium-antagonists and  
15 5-HT<sub>1B/1D</sub>-agonists.
3. The method according to claim 2, characterized in that drug (A) is selected from  
the group consisting of ergot alkaloids and 5-HT<sub>1B/1D</sub>-agonists.
- 20 4. The method according to claim 3, characterized in that the ergot alkaloid is  
ergotamine or dihydroergotamine or a physiologically acceptable salt thereof and  
the 5-HT<sub>1B/1D</sub>-agonist is almotriptan, avitriptan, eletriptan, frovatriptan, naratriptan,  
rizatriptan, sumatriptan or zolmitriptan or a physiologically acceptable salt thereof.
- 25 5. The method according to claim 1, characterized in that drug (A) is sumatriptan,  
zolmitriptan or dihydroergotamine or a physiologically acceptable salt thereof.
6. The method of claim 5, characterized in that BIBN4096BS or a physiologically  
acceptable salt thereof is administered by intravenous or subcutaneous route in a  
30 dosage of 0.0001 to 3 mg/kg of body weight or by oral, nasal or inhalative route in a  
dosage of 0.1 to 10 mg/kg of body weight once, twice or trice a day and

- 26 -

sumatriptan or a physiologically acceptable salt thereof is administered by oral route in a dosage of 0.03 to 1.43 mg/kg of body weight once, twice or trice a day or

5 by intravenous or subcutaneous route in a dosage of 0.002 to 0.09 mg/kg of body weight once or twice a day or

by rectal route in a dosage of 0.007 to 0.36 mg/kg of body weight once or twice a day or

10 by nasal route in a dosage of 0.006 to 0.29 mg/kg of body weight once or twice a day or

Zolmitriptan or a physiologically acceptable salt thereof is administered by oral route in a dosage of 0.0007 to 0.036 mg/kg of body weight once or twice a day or

15 dihydroergotamine or a physiologically acceptable salt thereof is administered by oral route in a dosage of 0.001 to 0.07 mg/kg of body weight once or twice a day.

7. A pharmaceutical composition for treating or preventing headache, migraine or  
20 cluster headaches comprising a therapeutically effective amount of BIBN4096BS or a physiologically acceptable salt thereof and an antimigraine drug (A) selected from the group consisting of sumatriptan, zolmitriptan and dihydroergotamin or a physiologically acceptable salt thereof as a combined preparation for simultaneous or sequential administration.

25

8. The pharmaceutical composition of claim 7 comprising a single dosage unit of 0.1 to 10 mg of BIBN4096BS and

30

a single dosage unit of 1 to 100 mg of sumatriptan or

a single dosage unit of 0.1 to 2.5 mg of zolmitriptan or

- 27 -

a single dosage unit of 0.1 to 5 mg of dihydroergotamin.

9. A kit of parts for treating or preventing headache, migraine or cluster headaches; which kit comprises

- 5 (c) a first containment containing a pharmaceutical composition comprising a therapeutically effective amount of BIBN4096BS or a physiologically acceptable salt thereof and one or more pharmaceutically acceptable diluents and/or carriers; and
- 10 (d) a second containment containing a pharmaceutical composition comprising sumatriptan, zolmitriptan or dihydroergotamin or a physiologically acceptable salt thereof and one or more pharmaceutically acceptable diluents and/or carriers.

10. The kit of parts according to claim 9, which kit comprises sumatriptan or a  
15 physiologically acceptable salt thereof in the second containment.

11. Use of BIBN4096BS or a physiologically acceptable salt thereof in combination with another active antimigraine drug (A) for the manufacture of a pharmaceutical composition for treating or preventing headache, migraine or cluster headaches.  
20

12. The use according to claim 11, characterized in that drug (A) is selected from the group consisting of antiemetics, prokinetics, neuroleptics, antidepressants, neurokinin-antagonists, anti-convulsants, histamine-H1-receptor antagonists, antimuscarinics,  $\beta$ -blockers,  $\alpha$ -agonists and  $\alpha$ -antagonists, ergot alkaloids, mild  
25 analgesics, non-steroidal antiphlogistics, corticosteroids, calcium-antagonists and 5-HT<sub>1B/1D</sub>-agonists.

13. The use according to claim 12, characterized in that drug (A) is selected from the group consisting of 5-HT<sub>1B/1D</sub>-agonists and ergot alkaloids.  
30

14. The use according to claim 13, characterized in that the ergot alkaloid is ergotamine or dihydroergotamine or a physiologically acceptable salt thereof and

- 28 -

the of 5-HT<sub>1B/1D</sub>-agonist is almotriptan, avitriptan, eletriptan, frovatriptan, naratriptan, rizatriptan, sumatriptan or zolmitriptan or a physiologically acceptable salt thereof.

15. The use according to claim 14, characterized in that drug (A) is sumatriptan,  
5 zolmitriptan or dihydroergotamin or a physiologically acceptable salt thereof.

16. The use of BIBN4096BS or a physiologically acceptable salt thereof for  
manufacture of a pharmaceutical composition or a kit of parts according to any of  
claims 7 to 10.

10

## INTERNATIONAL SEARCH REPORT

Inte      d Application No  
PCT/EP 02/08993

## A. CLASSIFICATION OF SUBJECT MATTER

IPC 7    A61K31/517    A61K31/422    A61K31/4045    A61K31/48    A61P29/00  
A61P25/06    //(A61K31/517,31:422), (A61K31/517,31:4045),  
(A61K31/517,31:48)

According to International Patent Classification (IPC) or to both national classification and IPC

## B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 7    A61P    A61K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

EPO-Internal, WPI Data, PAJ, EMBASE, MEDLINE, BIOSIS, CHEM ABS Data

## C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Y	DOODS H ET AL: "PHARMACOLOGICAL PROFILE OF BIBN4096BS, THE FIRST SELECTIVE SMALL MOLECULE CGRP ANTAGONIST" BRITISH JOURNAL OF PHARMACOLOGY, BASINGSTOKE, HANTS, GB, vol. 129, no. 3, 2000, pages 420-423, XP000992559 ISSN: 0007-1188 abstract	1-4, 11-13,16
A	---	5-10,14, 15
	---	---



Further documents are listed in the continuation of box C.



Patent family members are listed in annex.

## \* Special categories of cited documents:

- \*A\* document defining the general state of the art which is not considered to be of particular relevance
- \*E\* earlier document but published on or after the international filing date
- \*L\* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- \*O\* document referring to an oral disclosure, use, exhibition or other means
- \*P\* document published prior to the international filing date but later than the priority date claimed

\*T\* later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

\*X\* document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

\*Y\* document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.

\*Z\* document member of the same patent family

Date of the actual completion of the international search

18 November 2002

Date of mailing of the international search report

27/11/2002

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2  
NL - 2260 HV Rijswijk  
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,  
Fax: (+31-70) 340-3016

Authorized officer

Herrera, S

## INTERNATIONAL SEARCH REPORT

Inter al Application No

PCT/EP 02/08993

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT		
Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
P, Y	FERRARI M D ET AL: "Oral triptans (serotonin 5-HT <sub>1B/1D</sub> agonists) in acute migraine treatment: a meta-analysis of 53 trials" LANCET, XX, XX, vol. 358, no. 9294, 17 November 2001 (2001-11-17), pages 1668-1675, XP004323637 ISSN: 0140-6736	1-4, 11-13, 16
A	abstract	5-10, 14, 15
Y	DATABASE MEDLINE 'Online! 15 November 1993 (1993-11-15) HOERNECKE R ET AL: "'Treatment of migraine attacks: combination of dihydroergotamine tartrate and paracetamol in comparison with individual drugs and placebo!" Database accession no. NLM8295604 XP002199881	1-4, 11-13, 16
A	abstract	5-10, 14, 15
	& MEDIZINISCHE KLINIK (MUNICH, GERMANY: 1983) GERMANY 15 NOV 1993, vol. 88, no. 11, 15 November 1993 (1993-11-15), pages 642-648, ISSN: 0723-5003	
Y	DATABASE MEDLINE 'Online! January 1992 (1992-01) SAADAH H A: "Abortive headache therapy with intramuscular dihydroergotamine." Database accession no. NLM1555927 XP002216638	1-4, 11-13, 16
A	abstract	5-10, 14, 15
	& HEADACHE. UNITED STATES JAN 1992, vol. 32, no. 1, January 1992 (1992-01), pages 18-20, ISSN: 0017-8748	
A	WO 01 10425 A (BOEHRINGER INGELHEIM PHARMA ; EBERLEIN WOLFGANG (DE); DOODS HENRI () 15 February 2001 (2001-02-15) claims	1-16
A	WO 98 11128 A (EBERLEIN WOLFGANG ; ENTZEROTH MICHAEL (DE); HALLERMAYER GERHARD (DE) 19 March 1998 (1998-03-19) cited in the application page 173, line 6-11	1-16

# INTERNATIONAL SEARCH REPORT

International application No.  
PCT/EP 02/08993

## Box I Observations where certain claims were found unsearchable (Continuation of item 1 of first sheet)

This International Search Report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☒ Claims Nos.:  
because they relate to subject matter not required to be searched by this Authority, namely:  
see FURTHER INFORMATION sheet PCT/ISA/210
2. ☐ Claims Nos.:  
because they relate to parts of the International Application that do not comply with the prescribed requirements to such an extent that no meaningful International Search can be carried out, specifically:
3. ☐ Claims Nos.:  
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

## Box II Observations where unity of invention is lacking (Continuation of item 2 of first sheet)

This International Searching Authority found multiple inventions in this International application, as follows:

1. ☐ As all required additional search fees were timely paid by the applicant, this International Search Report covers all searchable claims.
2. ☐ As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3. ☐ As only some of the required additional search fees were timely paid by the applicant, this International Search Report covers only those claims for which fees were paid, specifically claims Nos.:
4. ☐ No required additional search fees were timely paid by the applicant. Consequently, this International Search Report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

### Remark on Protest

- ☐ The additional search fees were accompanied by the applicant's protest.  
☐ No protest accompanied the payment of additional search fees.

**FURTHER INFORMATION CONTINUED FROM PCT/ISA/ 210**

Continuation of Box I.1

Although claims 1-6 are directed to a method of treatment of the human/animal body, the search has been carried out and based on the alleged effects of the compound/composition.

---

Continuation of Box I.1

Rule 39.1(iv) PCT - Method for treatment of the human or animal body by therapy

# INTERNATIONAL SEARCH REPORT

Information on patent family members

Inter al Application No

PCT/EP 02/08993

Patent document cited in search report		Publication date	Patent family member(s)	Publication date
WO 0110425	A	15-02-2001	DE 19937304 A1	15-03-2001
			AU 6992800 A	05-03-2001
			BG 6391 A	30-09-2002
			BR 0013009 A	30-04-2002
			CN 1370069 T	18-09-2002
			CZ 20020497 A3	12-06-2002
			WO 0110425 A2	15-02-2001
			EP 1207884 A2	29-05-2002
			NO 20020605 A	07-02-2002
			SK 1972002 A3	04-06-2002
			TR 200200359 T2	21-05-2002
WO 9811128	A	19-03-1998	DE 19636623 A1	12-03-1998
			DE 19720011 A1	19-11-1998
			AU 721035 B2	22-06-2000
			AU 4119697 A	02-04-1998
			BG 103250 A	31-05-2000
			BR 9712023 A	31-08-1999
			CN 1230196 A	29-09-1999
			CZ 9900823 A3	16-06-1999
			EE 9900115 A	15-10-1999
			WO 9811128 A1	19-03-1998
			EP 0927192 A1	07-07-1999
			HR 970481 A1	31-08-1998
			JP 2000505100 T	25-04-2000
			NO 991130 A	05-05-1999
			NZ 334543 A	23-06-2000
			PL 331989 A1	16-08-1999
			SK 29799 A3	13-03-2000
			TR 9900537 T2	21-07-1999
			US 6344449 B1	05-02-2002
			ZA 9708083 A	17-12-1999
			HU 9904501 A2	28-04-2000